
#384 - Special episode — Obicetrapib: The CETP inhibitor with cardiovascular benefits and potential Alzheimer's prevention
Episode 384
View the Show Notes Page for This Episode Become a Member to Receive Exclusive Content Sign Up to Receive Peter's Weekly Newsletter In this special episode, Peter takes a deep dive into obicetrapib, an investigational drug that has captured his attention and renewed interest in an entire class of therapies known as CETP inhibitors. He explains what obicetrapib is and how it works, revisits the history of CETP inhibitors and why earlier versions of these drugs failed—sometimes dramatically—and breaks down the key clinical trials designed to evaluate their impact on cardiovascular risk. Peter examines how obicetrapib influences major lipid biomarkers, including LDL cholesterol and lipoprotein(a) [Lp(a)], and discusses emerging evidence from a study that explored the drug's effects on Alzheimer's-related blood biomarkers. He also highlights intriguing findings in individuals carrying the APOE4 allele and reflects on what these early results may mean for both cardiovascular disease prevention and potential implications for Alzheimer's risk, as well as how he is thinking about this therapy in the context of caring for his own patients.
Publisher
The Peter Attia Drive
Link
peterattiamd.com/obicetrapib/?utm_source=podcast-feed&utm_medium=referral&utm_campaign=260316-pod-obicetrapib&utm_content=260316-pod-obicetrapib-podfeed
Published
March 16, 2026
Duration
53 min
Format
Podcast
Category
Lifestyle · Health & Wellness
Source
RSS feed
Host
Peter Attia, MD
The Peter Attia Drive
@peterattiadrive
#cetpinhibitor #cardiovascularbenefits #potentialalzheimersprevention
